Licensing Agreement Announced for New Pain Treatment

Tikvah Therapeutics Inc. and Apkarian Technologies LLC announced Monday that Tikvah entered into an exclusive licensing agreement with Apkarian for patents and patent applications involving potential treatments for chronic pain. These rights provide Tikvah with patent claims that encompass the chronic treatment of pain and pain-related indications with glycine receptor agonists, substances that bind to receptors and trigger a response from the cell, as a standing-alone therapy or in combination therapy with certain other agents. This technology, developed by Dr. A. Vania Apkarian, sug...